Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)
Nicole S. McKay, Brian A. Gordon, Russ C. Hornbeck, Aylin Dincer, Shaney Flores, Sarah Keefe, Nelly Joseph‐Mathurin, Clifford R. Jack, Robert A. Koeppe, Peter R Millar, Beau M. Ances, Charles D. Chen, Alisha Daniels, Diana A. Hobbs, Kelley Jackson, Deborah Koudelis, Parinaz Massoumzadeh, Austin McCullough, Michael L. Nickels, Farzaneh Rahmani, Laura Swisher, Qing Wang, Ricardo Allegri, Sarah Berman, Adam M. Brickman, William S. Brooks, David M. Cash, Jasmeer P. Chhatwal, Gregory S. Day, Martin R. Farlow, Christian la Fougère, Nick C. Fox, Michael Fulham, Bernardino Ghetti, Neill R. Graff‐Radford, Takeshi Ikeuchi, William E. Klunk, Jae‐Hong Lee, Johannes Levin, Ralph N. Martins, Colin L. Masters, Jonathan McConathy, Hiroshi Mori, James M. Noble, Gerald Reischl, Christopher C. Rowe, Stephen Salloway, Raquel Sánchez‐Valle, Peter R. Schofield, Hiroyuki Shimada, Mikio Shoji, Yi Su, Kazushi Suzuki, Jonathan Vöglein, Igor Yakushev, Carlos Cruchaga, Jason Hassenstab, Celeste M. Karch, Eric McDade, Richard J. Perrin, Chengjie Xiong, John C. Morris, Randall J. Bateman, Tammie L.S. Benzinger, the Dominantly Inherited Alzheimer Network, Adam M. Brickman, Christian la Fougère
Abstract
The Dominantly Inherited Alzheimer Network (DIAN) is an international collaboration studying autosomal dominant Alzheimer disease (ADAD). ADAD arises from mutations occurring in three genes. Offspring from ADAD families have a 50% chance of inheriting their familial mutation, so non-carrier siblings can be recruited for comparisons in case-control studies. The age of onset in ADAD is highly predictable within families, allowing researchers to estimate an individual's point in the disease trajectory. These characteristics allow candidate AD biomarker measurements to be reliably mapped during the preclinical phase. Although ADAD represents a small proportion of AD cases, understanding neuroimaging-based changes that occur during the preclinical period may provide insight into early disease stages of 'sporadic' AD also. Additionally, this study provides rich data for research in healthy aging through inclusion of the non-carrier controls. Here we introduce the neuroimaging dataset collected and describe how this resource can be used by a range of researchers.